Tenapanor

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Kidney Disease Requiring Chronic Dialysis

Conditions

Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia

Trial Timeline

Nov 20, 2020 → Dec 1, 2021

NCT ID

NCT04549597

About Tenapanor

Tenapanor is a approved stage product being developed by Ardelyx for Chronic Kidney Disease Requiring Chronic Dialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT04549597. Target conditions include Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06810167	Phase 3	Recruiting	Jun 1, 2025	Jun 30, 2027	Cystic Fibrosis
NCT05995899	Approved	Completed	Feb 6, 2024	Dec 17, 2025	IBS
NCT06203444	Phase 1	Completed	Nov 27, 2023	May 30, 2024	Lactation
NCT05905926	Phase 3	Recruiting	Feb 17, 2023	Oct 1, 2031	Irritable Bowel Syndrome With Constipation (IBS-C)
NCT04549597	Approved	Completed	Nov 20, 2020	Dec 1, 2021	Chronic Kidney Disease Requiring Chronic Dialysis
NCT02727751	Phase 3	Completed	Mar 1, 2016	Oct 1, 2017	Constipation Predominant Irritable Bowel Syndrome

Competing Products

20 competing products in Chronic Kidney Disease Requiring Chronic Dialysis

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Ardelyx

Tenapanor + Sevelamer CarbonateApproved

TenapanorApproved

TenapanorPhase 3

Tenapanor 5 mg BID + Tenapanor 25 mg BID + Tenapanor 50 mg BID + PlaceboPhase 3